- Home
- GALT vs TNYA Comparison
GALT vs TNYA Comparison
Compare GALT & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GALT | TNYA |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.2M | 178.5M |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GALT | TNYA |
|---|---|---|
| Price | $2.68 | $0.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $8.50 | $5.33 |
| AVG Volume (30 Days) | 319.4K | ★ 5.0M |
| Earning Date | 03-31-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 36.84 | ★ 54.96 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,456.12 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.15 | $0.36 |
| 52 Week High | $7.13 | $2.35 |
Technical Indicators
Market Signals| Indicator | GALT | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 42.03 | 43.92 |
| Support Level | $2.59 | $0.66 |
| Resistance Level | $3.32 | $0.70 |
| Average True Range (ATR) | 0.20 | 0.06 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 15.75 | 21.90 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.